UPCOMING WEBINAR
February 12, 2026, 12:00pm Eastern Time
Webinar Description:
Metastasis-directed therapy (MDT) using stereotactic body radiotherapy (SBRT) has emerged as an important strategy in the management of select patients with metastatic renal cell carcinoma (RCC), particularly in the oligometastatic and oligoprogressive settings. This webinar will review the biological and clinical rationale for MDT in RCC, with a focus on delaying initiation or escalation of systemic therapy while maintaining disease control and quality of life. A multidisciplinary panel of medical and radiation oncologists will summarize the key prospective and retrospective data supporting MDT, contrast its role in oligometastatic versus oligoprogressive disease, and illustrate real-world application through representative clinical cases.
Educational Objectives:
Discuss the rationale for considering metastasis-directed therapy in patients with metastatic RCC.
Review published clinical outcomes of MDT in oligometastatic and oligoprogressive RCC.
Apply MDT concepts to clinical decision-making using representative patient case scenarios.
Advances in the applications, technologies and methodologies of stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) continue to evolve rapidly and the delivery of treatment has become more complex, making it imperative that oncology professionals remain current in the state-of-the-art techniques. The Radiosurgery Society is committed to providing educational programming that creates a forum for global collaboration to improve professional practice by increasing their level of knowledge, as required to improve competency in the field of oncology.
The target audience includes radiation oncologists, surgeons, medical physicists, nurses, residents, trainees and healthcare providers in the field of SRS/SBRT, radiation oncology and medical oncology.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and The Radiosurgery Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
<em>No financial commercial support was received for this educational activity.</em>
<em>No in-kind commercial support was received for this educational activity.</em>
If continuing education credits are applicable for this webinar, a certificate will be issued upon completion of course requirements, including the online evaluation, enabling you to register your credit with the appropriate licensing boards or associations. Evaluations must be completed within 45 days of live webinar.
Please contact webinars@therss.org if you have questions.